NEW YORK, March 25, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Global CNS Therapeutics Industryhttp://www.reportlinker.com/p01139068/Global-CNS-Therapeutics-Industry.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Therapy
This report analyzes the worldwide markets for CNS Therapeutics in US$ Million by the following Product Groups: Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management (includes Migraine, Nociceptive and neuropathic pain), Anti-Psychotics, Anti-Depressants, and Others (includes Multiple Sclerosis, Insomnia and ADHD). The report provides separate comprehensive analytics for the US, Canada, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2010 through 2018.
The report profiles 127 companies including many key and niche players such as AbbVie Inc., Alkermes Plc, Amneal Pharmaceuticals, LLC, Aspen Pharmacare Holdings Limited, AstraZeneca Plc, BEACON Pharmaceutical Limited, BIAL Group, Boehringer Ingelheim GmbH, Bristol-Myers Squibb, Dainippon Sumitomo Pharma Co., Ltd., Eisai Co., Ltd., Elan Corporation Plc, Eli Lilly and Co., F. Hoffmann-La Roche Ltd., Fabre-Kramer Pharmaceuticals, Inc., Forest Laboratories, Inc., GlaxoSmithKline, H. Lundbeck A/S, Johnson & Johnson, Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Neurocrine Biosciences, Inc., Novartis AG, Otsuka Pharmaceutical Co., Ltd., Pfizer, Inc., Sanofi S.A, Shire Plc, Sunovion Pharmaceuticals, Inc., Takeda Pharmaceutical Co., Ltd., Teva Pharmaceutical Industries Ltd., and UCB Group.
Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain.
I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONSStudy Reliability and Reporting Limitations I-1Disclaimers I-2Data Interpretation & Reporting Level I-2Quantitative Techniques & Analytics I-3Product Definitions and Scope of Study I-3CNS Disorders I-3Anti-Alzheimer's Drugs I-3Anti-Parkinson's Drugs I-4Anti-Epilepsy Drugs I-4Pain Management Drugs I-4Anti-Psychotics Drugs I-5Bipolar disorder I-5Schizophrenia I-5Anti-Depressants Drugs I-5Others I-6Attention Deficit Hyperactivity Disorder I-6Multiple Sclerosis I-6Insomnia I-6Restless Legs Syndrome I-7Anxiety I-7
II. EXECUTIVE SUMMARY
1. INDUSTRY OVERVIEW II-1CNS Diseases, Treatment & Therapeutics: A Primer II-1CNS Drugs: The Next Big Thing in the Healthcare Industry II-1Major Growth Drivers in a Capsule II-2Noteworthy Market Trends/Drivers & Issues II-2Aging Population: A Key Demand Propellant II-2Table 1: Percentage Share Breakdown of Global Population byAge Group, Worldwide: 2025 (includes correspondingGraph/Chart) II-3
Table 2: World Population of People Aged 65+ Years (InMillion) for Years 2012, 2020 & 2050 (includes correspondingGraph/Chart) II-4Developments in CNS Drug Delivery Technologies Bode Well forthe CNS Drugs Market II-4Understanding of BBB Cell Biology & Its Positive Impact onEpilepsy Drugs: A Case-in-Point II-4Healthcare Cost Rationing & Government Caps Challenge BrandedCNS Drugs II-5Slew of Imminent Patent Expiries to Exert Downward Pressureon the CNS Drugs Market II-6Patent Expiries of Leading CNS Drugs: 2008-2022 II-7Branded Generic CNS Drugs: A Key Revenue Spinner in EmergingCountries II-8Focused R&D Efforts: Need of the Hour II-8Need Factor in the Epilepsy Market: A Case-In-Point II-8Pharma Companies: Seeking New Tools to Offset Pressure onDrug Pipelines II-9Huge Unmet Medical Needs Underpin Market Potential II-10A Special Focus on the Unmet Needs in Epilepsy II-10Awareness Campaigns Launched by Pharma Companies to Benefitthe Market II-11
2. MARKET OVERVIEW & TRENDS ACROSS CNS THERAPEUTIC AREAS II-12Anti-Epilepsy II-12Market Overview II-12Table 3: Global Sales of Select Leading Anti-Epilepsy DrugBrands In US$ Million for the Year 2011 (includescorresponding Graph/Chart) II-13A Peek into Select Epilepsy Drugs Currently Available in theMarketplace II-13A Peek Into Few of the Popular Anti-Epileptic Drugs andTheir Mechanism of Action II-15Higher Incidences in Developing Countries II-15Abounding Potential for NCEs II-15A Peek into Select Epilepsy Drugs in Clinical Development Asof the Year 2012 II-16A Peek into Select Anti-Epileptic Drugs Approved in theYears 2011 & 2012 II-17Pregnancy Safe Anti-Epileptic Drugs: Need of the Hour II-17CNS Pain Management II-17Market Overview II-17Combination Therapies Gain Prominence II-18Migraine Market Offers Growth Opportunities to ProphylaxisProducts II-18Neuropathic Pain Management: A Potential Laden Market II-19Strong Product Pipeline to Benefit the Neuropathic PainManagement Market II-19Anti-Alzheimer's II-20Market Overview II-20Anti-Parkinson's II-20Market Overview II-20Anti-Depressants II-21Market Overview II-21Attention Deficit Hyperactivity Disorder (ADHD) II-21Market Overview II-21Anti-Psychotics II-22Market Overview II-22Prevalence of Schizophrenia and Bipolar Disorders:Statistical Snippets II-22Second Generation Antipsychotics Beset With Safety Issues II-23Companies Focus on Next Generation Products To Deflect theHeat of Competition II-23Table 4: World Antipsychotics Market (2011): Sales ofLeading Drug Brands - Seroquel IR, Seroquel XR, Abilify,Zyprexa & Zyprexa Relprevv, Risperdal & Risperdal Consta,Geodon, and Invega & Invega Sustenna (In US$ Million)(includes corresponding Graph/Chart) II-24A Peek into Anti-Psychotic Drugs in Late-Stage ClinicalDevelopment As of 2012 II-25
3. CHANGING HEALTHCARE INDUSTRY IN EUROPE & THE UNITED STATES II-26Healthcare Economics, the Eurozone Crisis & Changing Role ofthe Government in Europe's Healthcare System II-26Impact of Europe's Rationing Healthcare System On CNS Drugs II-27Impact On Pharma Companies in Europe II-28Outlook for CNS Therapeutics in the United States in Light ofthe Fiscal Cliff II-30
4. PRODUCT OVERVIEW II-32Definition II-32Central Nervous System II-32Mortality Threat of CNS Disorders II-32Science of NMDA Receptors and its Disease Significance II-32Major CNS Disorders: II-33Alzheimer's Disease II-33Alzheimer's Affect on Brain II-33Causes for Alzheimer's II-34Who Are at Risk? II-34Prevalence of Alzheimer's Disease II-35Diagnosis of Alzheimer's II-35Treatment for Alzheimer's II-35Parkinson's Disease II-36Prevalence of Parkinson's II-36Symptom of Parkinson's II-36Causes of Parkinson's II-37Parkinson's Diagnosis II-37Therapies for Parkinson's II-38Surgery: The Last Option II-38Epilepsy II-38Causes of Epilepsy II-38Symptoms of Epilepsy II-39Types of Epilepsy and Epileptic Seizures II-39Preventive Measures II-40Treatment Options for Epilepsy Patients II-40Treatment Options Available for Epilepsy Patients II-41Epilepsy Drug Treatment Paradigm II-41Pain Management II-41Debilitating Effects of Pain II-42Types of Pain II-42Acute Pain II-42Chronic Pain II-42Migraine II-43Neuropathic Pain II-43Nociceptive Pain II-43Pain Management Therapies II-43Bipolar Disorder II-44Symptoms of Bipolar Disorder II-44Mood Episode - A Major Symptom II-44Manic Episode Vs Depressive Episode II-45Causes of Bipolar Disorder II-45Types of Bipolar Disorder II-46Co-morbidities of Bipolar Disorder II-46Schizophrenia II-46Prevalence by Gender II-47Symptoms of Schizophrenia II-47Causes of Schizophrenia II-48Therapies for Bipolar Disorder & Schizophrenia II-48Mood Stabilizing Agents II-49Antidepressants II-49Antipsychotic Drugs II-49Indications of Antipsychotics II-50An Effective Adjunctive Therapy II-50Off-label Uses II-50Efficacy - Marred by Lack of Evidence Base II-50Types of Antipsychotics II-51Difference between Typical and Atypical II-51Atypical Antipsychotics Up Against Typicals II-51Side Effects of Antipsychotics II-52Symptoms of Antipsychotics Withdrawal II-53Controversies Surrounding Antipsychotics II-54Prohibited Practices II-54Antipsychotics in Pregnant Women II-54Depression II-55Prevalence of Depression II-55Causes of Depression II-55Types of Depressive Disorders II-56Available Treatment II-56Tricyclic Antidepressants II-56Monoamine Oxidase Inhibitors II-56Lithium Salts II-56Working of Antidepressants II-57Ranking of Antidepressants in Terms of Efficacy II-57Types of Antidepressants II-57NMDA Receptor Antagonists II-57NMDA Receptor (NMDAR) II-57NMDA Receptor Agonists II-58Acetylcholinesterase Inhibitors II-58Selective Serotonin Reuptake Inhibitors (SSRIs) II-58Workings of SSRIs II-59Safety Levels of SSRI Drugs II-59Adverse Effects of SSRI II-59Serotonin Noradrenaline Reuptake Inhibitors (SNRIs) II-59Others Common CNS Disorders II-60Attention Deficit Hyperactivity Disorder II-60Consequences of ADHD II-60What Leads to ADHD? II-60Treating ADHD II-61Multiple Sclerosis (MS) II-61Types of Multiple Sclerosis II-61Prevalence of MS II-62Causes of MS II-62Myths Surrounding Multiple Sclerosis II-62Symptoms of MS II-62Diagnosis of MS II-62Therapies for MS II-63Insomnia II-63Prevalence of Insomnia II-63Therapies for Insomnia II-63Restless Legs Syndrome II-63Anxiety II-64
5. REVIEW OF SELECT CNS DRUGS II-65Anti-Alzheimer's Drugs II-65Aricept II-65Exelon II-65Reminyl II-65Ebixa II-65Namenda II-65Anti-Parkinson's Drugs II-66Levodopa II-66Dopamine Agonists II-66Mirapex II-66Requip II-66Anti-Epilepsy Drugs II-66Vimpat® II-67Keppra® II-67Lamictal II-68Tegretol® II-68Sabril® II-68Perampanel II-68Zonegran® II-68Topamax® II-69Trileptal® II-69Neurontin® II-69Lyrica® II-69Depakine® II-69Pain Management II-70Flupirtine II-70Lyrica® II-70Oxycodone II-70Nucynta ER II-70Cymbalta® II-70Metabotropic Glutamate Receptors (mGluRs) II-70Anti-Psychotic Drugs II-71Zyprexa II-71Seroquel II-71Abilify II-72Clozaril II-72Risperdal II-72Risperdal® Consta® II-72Geodon II-73Invega Sustenna II-73Saphris II-73Latuda II-73Antidepressants Drugs II-74Zoloft (Sertraline) II-74Prozac (Fluoxetine) II-74Effexor (Venlafaxine) II-74Paxil II-74Wellbutrin (Bupropion) II-74Attention Deficit Hyperactivity Disorder (ADHD) II-75Concerta II-75Strattera II-75Adderall II-75Insomnia II-75Zolpidem II-76Eszopiclone II-76
6. RESEARCH & DEVELOPMENT II-77Research Finds Higher Diabetes Risk among Antipsychotic-Treated Patients II-77Zonisamide is Effective in Epilepsy Prevention in Children II-77Latuda Effective in Bipolar I Depression Treatment II-77Cariprazine Effective in Bipolar I Disorder Treatment II-78Alkermes Initiates Phase III Clinical Trials of InvegaSustenna II-78Antipsychotics Increase Mortality Risk in Dementia Patients II-78Potential Antipsychotic Drug Fails in Clinical Study II-79Pfizer Discontinues Clinical Trial of Lyrica Capsules CV II-79Cariprazine Shows Efficacy in Acute Schizophrenia Treatment II-79Prevention of Neuropathic Pain through Saxitoxin DexamethasoneLiposomes II-79Perampanel Effective in Reducing Epileptic Seizures II-80Targacept Initiates Trials of its Novel Schizophrenia Drug II-80Vertex Develops VX-765 for Epilepsy II-80ALKS 9070 Effective in Treatment of Schizophrenia II-80Lyrica Effective in Central Neuropathic Pain Following SpinalCord Injury II-81UCB's Vimpat Reduces Partial-Onset Seizure II-81Eisai Announces Encouraging Results for Perampanel II-81
7. PRODUCT INTRODUCTIONS/INNOVATIONS II-82Eisai Launches Fycompa II-82Dr Reddy's Unveils Generic Zyprexa in the US II-82Eisai Europe Launches Zebinix® Eslicarbazepine Acetate II-82Sun Pharma, Lupin and Dr Reddy's Introduce GenericSchizophrenia Drug II-82Mylan Launches Levetiracetam in Sodium Chloride Injection II-82Dr. Reddy's Laboratories Introduces Generic Antipsychotic Drug II-83Eisai to Unveil Fycompa Antiepileptic Agent II-83H. Lundbeck Introduces Sycrest II-83GW Pharmaceuticals to Develop Cannabis-Based EpilepticTreatment II-83Sun Pharmaceutical Unveils Zyprexa Zydis II-84Eisai to Unveil Zonegran Drug Treatment in Russia II-84Teva Pharmaceutical Industries Introduces Quetiapine andQuetiapine XL II-84Eisai and Nobelpharma to Introduce Fostoin AnticonvulsantAgent II-84Janssen Pharmaceuticals Receives Approval for Updated ProductLabeling II-84H Lundbeck Introduces Onfi Anti-Epileptic Drug in US II-85Amneal Pharmaceuticals Unveils Felbamate Generic Anti-Epileptic Drug II-85Teva UK Unveils Generic Olanzapine for Schizophrenia II-85Mylan Pharmaceuticals Unveils Divalproex Sodium Capsules USP II-86Actavis Introduces Generic Olanzapine Tablets II-86GlaxoSmithKline Introduces Trobalt® Anti-Epileptic Drug II-86Alkermes Launches Phase III Clinical Trial for Drug CandidateALKS 9070 II-86BIAL and Eisai Unveil Zebinix® Drug in Spain II-86Amneal Launches AA-Rated Generic Oral Drugs II-86Orexo Introduces Analgesic Drug Abstral II-87MSN Laboratories Unveils Tapal for Pain Management II-87CNS Pain Management Company Introduces Palexia® SR II-87Glenmark Genetics Introduces New Formulations for PainManagement II-87Vanda Pharmaceuticals Introduces Fanapt for Schizophrenia II-88Roche to Develop RG-1678 Schizophrenia Drug II-88H. Lundbeck and King's College London Launch Academic-IndustryCollaboration Project II-88Alkermes Develops LinkeRx™ technology Platform for CNSTherapies II-89Novartis Introduces Fanapt Schizophrenia Drug II-89Axxess Pharma Signs Agreement to Market Fortex II-89Nutra Pharma Unveils Cobroxin in CVS II-89
8. RECENT INDUSTRY ACTIVITY II-90UCB and Otsuka Pharmaceuticals to Develop Anti-Epileptic Drugs II-90Sunovion Files for Expanded Use of Latuda® II-90Eisai Receives Manufacturing License in the UK II-90Dainippon Sumitomo and Takeda Receive Acceptance from the EMA II-90Lupin Receives FDA Approval to Market Anti-Epileptic Drugs II-91Dainippon Sumitomo Inks an Agreement with Takeda II-91Sanofi and Alfresa Pharma Ink Agreement to Develop Vigabatrin II-91Sunovion Files two sNDAs for Latuda® II-91Prasco Laboratories Inks Agreement with Shire II-92Otsuka Files for Additional Indication for Abilify® II-92Aspen Global to Take Over Drug Portfolio of GlaxoSmithKline II-92Par Pharmaceutical and Handa Pharmaceuticals Ink LicensingAgreement II-92Upsher-Smith Laboratories Takes Over Proximagen Group II-92Mylan Pharmaceuticals Receives FDA Approval for LithiumCarbonate Extended-release Tablets USP II-93Supernus Obtains Approval for Oxtellar XR Anti-Epilepsy Drug II-93FDA Denies Antipsychotic Drug from Otsuka and Lundbeck II-93Eisai Receives Approval for Fycompa Drug II-93Forest Laboratories Submits NDA for Cariprazine II-94Lupin Pharmaceuticals Obtains Approval for LevetiracetamGeneric Drug II-94Johnson & Johnson Pays Fine for Illegal Marketing II-94UCB Discloses Epilepsy Drug Trial Results II-94GSK Agrees to Pay Criminal Fine for Illegal Promotion II-94GlaxoSmithKline Obtains Marketing Approval for Trobalt™ II-94Novartis Discontinues Development of Fanapt II-95Qualitest Pharmaceuticals Obtains FDA Approval forLevetiracetam Tablets II-95Eisai Europe Obtains Approval for Zonegran® Anti-EpilepticAgent II-95Eisai Obtains Approval for Zonegran® II-95Glenmark Generics Obtains FDA Approval for Lamotrigine II-96Mylan Obtains FDA Approval for Levetiracetam Extended-ReleaseTablets II-96Forest Laboratories Enters into Broad Strategic Alliance withmoksha8 II-96moksha8 Extends License Agreement with Watson Pharmaceuticals II-96Paladin Labs and QRxPharma Sign Licensing Agreement II-97Mallinckrodt Acquires CNS Therapeutics II-97Neurodyn Takes Over NeuroQuest II-97Zogenix Inks Exclusive Co-Promotion Agreement withMallinckrodt II-98Omron Healthcare Unveils Omron electroTHERAPY Pain Relief Unit II-98Watson Pharmaceuticals Rolls Out REPREXAINTM CIII II-99INSYS Therapeutics Launches SUBSYS™ Dosage Form for BTCPTreatment II-99Actavis Signs Agreement with QRxPharma to Market MOXDUO® IR II-99Mallinckrodt Receives FDA Approval for EXALGO® Tablet II-99Biostar Pharmaceuticals Obtains Army New Drug Certificate forZushima Analgesic Spray II-100Pfizer Receives FDA Approval for Lyrica® Capsules II-100Teva Acquires Cephalon II-100Eisai Files for Expanded Use of Zonegran II-100Johnson & Johnson Recalls Schizophrenia Drug II-101Intellipharmaceutics Files for NDA Approval for Lamictal XRGeneric Version II-101BioLineRx Receives New Patent Protection for SchizophreniaDrug II-101Aurobindo Pharmaceuticals Obtains FDA Approval for GabapentinTablets II-101Zogenix Acquires Rights to Utilize Durect's Technology forRelday II-101Unichem Obtains FDA Approval for Lamotrigine Tablets II-102BioLineRx Signs Agreement with Cypress Bioscience II-102Eisai Obtains Approval from Health Canada for Banzel II-102Alkermes Acquires Elan Drug Technologies II-102Eisai Obtains FDA Approval for Oral Suspension of Banzel II-103Pfizer Acquires Icagen II-103Health Canada Grants Approval for Abilify® to TreatSchizophrenia in Adolescents II-103GlaxoSmithKline Receives Approval for Rotavirus Vaccine andLamictal Tablets II-103Janssen Obtains Approval for Xeplion from European Commission II-104Janssen-Cilag Receives FDA Approval for INVEGA® II-104Janssen-Cilag International Secures EC Approval for INVEGA II-104Actavis Enters into Letter of Intent with QRxPharma II-104DSM Pharmaceutical and QRxPharma Ink Manufacturing and SupplyAgreement II-105UCB Takes Over Key Pharmaceutical Assets of LectusTherapeutics II-105Teva Pharmaceutical Industries Acquires Cephalon II-106Biotie Therapies Takes Over Newron Pharmaceuticals II-106RaQualia Pharma Enters into Collaboration with Eli Lilly II-106Elder Pharmaceuticals to Launch New Therapeutic Products II-107Lupin Pharmaceuticals Obtains FDA Approval for Tramadol ERTablets II-107Envoy Therapeutics and Takeda Pharmaceutical Form ResearchAlliance II-107Ranbaxy Recalls Anti-Epileptic Drug from UK II-107H. Lundbeck Inks Global Commercialization Agreement with Merck II-107Medco Research Institute to Form Alliance with SureGene II-108Forest Labs and Gruenenthal Sign License Agreement II-108Endo Pharmaceuticals Holdings Acquires QualitestPharmaceuticals II-108IntelGenx Inks an Agreement with PediPharm II-109Insys Therapeutics Merges with NeoPharm II-109HepaLife Technologies Collaborates with Jeiven Pharmaceutical II-109Pfizer to Take Over King Pharmaceuticals II-110The Apothecary Shops Takes Over Greater Sacramento SpecialtyPharmacy II-110NsGene and Biogen Idec Ink New Commercialization and LicenseAgreement II-110Xanodyne Pharmaceuticals Inks Co-Promotion Agreement withFerring Pharmaceuticals II-111QRxPharma Enters into Strategic Alliance with China AoxingPharmaceutical II-111Pfizer Japan Obtains New Indication Approval for Lyrica®Capsules II-111Eli Lilly and Company Receives FDA Approval for Cymbalta II-112
9. FOCUS ON SELECT GLOBAL PLAYERS II-113AbbVie Inc (USA) II-113Alkermes Plc (Ireland) II-113Amneal Pharmaceuticals, LLC (USA) II-114Aspen Pharmacare Holdings Limited (South Africa) II-115AstraZeneca Plc (UK) II-115BEACON Pharmaceutical Limited (UK) II-116BIAL Group (Portugal) II-116Boehringer Ingelheim GmbH (Germany) II-116Bristol-Myers Squibb (USA) II-117Dainippon Sumitomo Pharma Co., Ltd. (Japan) II-118Eisai Co., Ltd. (Japan) II-119Elan Corporation Plc (Ireland) II-120Eli Lilly and Co. (USA) II-120F. Hoffmann-La Roche Ltd. (Switzerland) II-121Fabre-Kramer Pharmaceuticals, Inc. (USA) II-121Forest Laboratories, Inc. (USA) II-122GlaxoSmithKline (UK) II-122H. Lundbeck A/S (Denmark) II-123Johnson & Johnson (USA) II-124Janssen Pharmaceuticals, Inc. (USA) II-125Merck & Co., Inc. (USA) II-125Neurocrine Biosciences, Inc. (USA) II-125Novartis AG (Switzerland) II-126Otsuka Pharmaceutical Co., Ltd. (Japan) II-127Pfizer, Inc. (USA) II-127Sanofi S.A (France) II-128Shire Plc (UK) II-130Sunovion Pharmaceuticals, Inc. (USA) II-130Takeda Pharmaceutical Co., Ltd. (Japan) II-130Teva Pharmaceutical Industries Ltd. (Israel) II-131UCB Group (Belgium) II-131
10. GLOBAL MARKET PERSPECTIVE II-133Table 5: World Recent Past, Current & Future Analysis for CNSTherapeutics by Geographic Region - US, Canada, Europe,Asia-Pacific, Latin America and Rest of World MarketsIndependently Analyzed by Annual Sales in US$ Million for theYears 2010 through 2018 (includes corresponding Graph/Chart) II-133
Table 6: World Historic Review for CNS Therapeutics byGeographic Region - US, Canada, Europe, Asia-Pacific, LatinAmerica and Rest of World Markets Independently Analyzed byAnnual Sales in US$ Million for the Years 2004 through 2009(includes corresponding Graph/Chart) II-134
Table 7: World 15-Year Perspective for CNS Therapeutics byGeographic Region - Percentage Breakdown of Value Sales forUS, Canada, Europe, Asia-Pacific, Latin America and Rest ofWorld Markets for the Years 2004, 2012 and 2018 (includescorresponding Graph/Chart) II-135
Table 8: World Recent Past, Current & Future Analysis forAnti-Alzheimer's by Geographic Region - US, Canada, Europe,Asia-Pacific, Latin America and Rest of World MarketsIndependently Analyzed by Annual Sales in US$ Million for theYears 2010 through 2018 (includes corresponding Graph/Chart) II-136
Table 9: World Historic Review for Anti-Alzheimer's byGeographic Region - US, Canada, Europe, Asia-Pacific, LatinAmerica and Rest of World Markets Independently Analyzed byAnnual Sales in US$ Million for the Years 2004 through 2009(includes corresponding Graph/Chart) II-137
Table 10: World 15-Year Perspective for Anti-Alzheimer's byGeographic Region - Percentage Breakdown of Value Sales forUS, Canada, Europe, Asia-Pacific, Latin America and Rest ofWorld Markets for the Years 2004, 2012 and 2018 (includescorresponding Graph/Chart) II-138
Table 11: World Recent Past, Current & Future Analysis forAnti-Parkinson's by Geographic Region - US, Canada, Europe,Asia-Pacific, Latin America and Rest of World MarketsIndependently Analyzed by Annual Sales in US$ Million for theYears 2010 through 2018 (includes corresponding Graph/Chart) II-139
Table 12: World Historic Review for Anti-Parkinson's byGeographic Region - US, Canada, Europe, Asia-Pacific, LatinAmerica and Rest of World Markets Independently Analyzed byAnnual Sales in US$ Million for the Years 2004 through 2009(includes corresponding Graph/Chart) II-140
Table 13: World 15-Year Perspective for Anti-Parkinson's byGeographic Region - Percentage Breakdown of Value Sales forUS, Canada, Europe, Asia-Pacific, Latin America and Rest ofWorld Markets for the Years 2004, 2012 and 2018 (includescorresponding Graph/Chart) II-141
Table 14: World Recent Past, Current & Future Analysis forAnti-Epilepsy by Geographic Region - US, Canada, Europe,Asia-Pacific, Latin America and Rest of World MarketsIndependently Analyzed by Annual Sales in US$ Million for theYears 2010 through 2018 (includes corresponding Graph/Chart) II-142
Table 15: World Historic Review for Anti-Epilepsy byGeographic Region - US, Canada, Europe, Asia-Pacific, LatinAmerica and Rest of World Markets Independently Analyzed byAnnual Sales in US$ Million for the Years 2004 through 2009(includes corresponding Graph/Chart) II-143
Table 16: World 15-Year Perspective for Anti-Epilepsy byGeographic Region - Percentage Breakdown of Value Sales forUS, Canada, Europe, Asia-Pacific, Latin America and Rest ofWorld Markets for the Years 2004, 2012 and 2018 (includescorresponding Graph/Chart) II-144
Table 17: World Recent Past, Current & Future Analysis forPain Management by Geographic Region - US, Canada, Europe,Asia-Pacific, Latin America and Rest of World MarketsIndependently Analyzed by Annual Sales in US$ Million for theYears 2010 through 2018 (includes corresponding Graph/Chart) II-145
Table 18: World Historic Review for Pain Management byGeographic Region - US, Canada, Europe, Asia-Pacific, LatinAmerica and Rest of World Markets Independently Analyzed byAnnual Sales in US$ Million for the Years 2004 through 2009(includes corresponding Graph/Chart) II-146
Table 19: World 15-Year Perspective for Pain Management byGeographic Region - Percentage Breakdown of Value Sales forUS, Canada, Europe, Asia-Pacific, Latin America and Rest ofWorld Markets for the Years 2004, 2012 and 2018 (includescorresponding Graph/Chart) II-147
Table 20: World Recent Past, Current & Future Analysis forAnti-Psychotics by Geographic Region - US, Canada, Europe,Asia-Pacific, Latin America and Rest of World MarketsIndependently Analyzed by Annual Sales in US$ Million for theYears 2010 through 2018 (includes corresponding Graph/Chart) II-148
Table 21: World Historic Review for Anti-Psychotics byGeographic Region - US, Canada, Europe, Asia-Pacific, LatinAmerica and Rest of World Markets Independently Analyzed byAnnual Sales in US$ Million for the Years 2004 through 2009(includes corresponding Graph/Chart) II-149
Table 22: World 15-Year Perspective for Anti-Psychotics byGeographic Region - Percentage Breakdown of Value Sales forUS, Canada, Europe, Asia-Pacific, Latin America and Rest ofWorld Markets for the Years 2004, 2012 and 2018 (includescorresponding Graph/Chart) II-150
Table 23: World Recent Past, Current & Future Analysis forAnti-Depressants by Geographic Region - US, Canada, Europe,Asia-Pacific, Latin America and Rest of World MarketsIndependently Analyzed by Annual Sales in US$ Million for theYears 2010 through 2018 (includes corresponding Graph/Chart) II-151
Table 24: World Historic Review for Anti-Depressants byGeographic Region - US, Canada, Europe, Asia-Pacific, LatinAmerica and Rest of World Markets Independently Analyzed byAnnual Sales in US$ Million for the Years 2004 through 2009(includes corresponding Graph/Chart) II-152
Table 25: World 15-Year Perspective for Anti-Depressants byGeographic Region - Percentage Breakdown of Value Sales forUS, Canada, Europe, Asia-Pacific, Latin America and Rest ofWorld Markets for the Years 2004, 2012 and 2018 (includescorresponding Graph/Chart) II-153
Table 26: World Recent Past, Current & Future Analysis forOthers by Geographic Region - US, Canada, Europe,Asia-Pacific, Latin America and Rest of World MarketsIndependently Analyzed by Annual Sales in US$ Million for theYears 2010 through 2018 (includes corresponding Graph/Chart) II-154
Table 27: World Historic Review for Others by GeographicRegion - US, Canada, Europe, Asia-Pacific, Latin America andRest of World Markets Independently Analyzed by Annual Salesin US$ Million for the Years 2004 through 2009 (includescorresponding Graph/Chart) II-155
Table 28: World 15-Year Perspective for Others by GeographicRegion - Percentage Breakdown of Value Sales for US, Canada,Europe, Asia-Pacific, Latin America and Rest of World Marketsfor the Years 2004, 2012 and 2018 (includes correspondingGraph/Chart) II-156
III. MARKET
1. THE UNITED STATES III-1A.Market Analysis III-1Current & Future Analysis III-1Market Overview III-1Focus on Select Markets III-1Alzheimer's Market III-1Anti-Epilepsy Market III-1Epilepsy - A Major Concern for Healthcare Industry III-1A Glance at Epilepsy Statistics III-2Anti-Epilepsy Drugs: Market Overview III-2Table 29: Number of Dispensed Prescriptions in the USAnti-Epileptic Drugs Market in Million (2007-2012)(includes corresponding Graph/Chart) III-3Epilepsy in Children III-3Growing Competition from Generics III-4Pain Management Market III-4Neuropathic Pain Market III-5Anti-Psychotic Drugs Market III-5Mental Illnesses - An Epidemiology III-5Facts & Figures III-5Table 30: Lifetime Prevalence (%) of Bipolar Disorder inthe US Population by Age Group (includes correspondingGraph/Chart) III-6Popular Antipsychotic Drugs in the US III-6Table 31: Sales of Select Anti-Psychotic Drugs in the US(2011) (In US$ Million) (includes correspondingGraph/Chart) III-7Anti-Psychotic Drugs by FDA Approved Age and Indicationin the US III-7Table 32: US Anti-Psychotic Drugs Market (2012):Percentage Breakdown of Value Sales by Indication -Bipolar Disorder, Schizophrenia, Major DepressiveDisorder, and Others (includes corresponding Graph/Chart) III-8
Table 33: US Antipsychotics Market (2012): PercentageShare Breakdown of Prescriptions by Indication - BipolarDisorder, Schizophrenia, Major Depressive Disorder,Anxiety, and Others (includes corresponding Graph/Chart) III-8
Table 34: Leading Brands in the US Antipsychotics Market(2011): Percentage Share Breakdown of Number ofPrescriptions by Seroquel, Abilify, Zyprexa, Geodon,Seroquel XR and Others (includes correspondingGraph/Chart) III-8
Table 35: Leading Antipsychotic Brands in the USSchizophrenia Market (2011): Percentage Share Breakdownof Number of Prescriptions by Seroquel, Abilify, Zyprexa,Geodon, Seroquel XR and Others (includes correspondingGraph/Chart) III-9Growth Dampeners III-9Surging Off-label Prescriptions III-9Advertising for Antipsychotics Acquires a Whole NewDimension III-10Table 36: Leading Brands in the US Antipsychotics Market(2011): Percentage Share Breakdown of PromotionalSpending by Abilify, Seroquel, Saphris, Geodon, Latuda,Invega, Zyprexa, and Others (includes correspondingGraph/Chart) III-10Illegal Marketing - A Cause of Concern for Governments III-10Generics Occupy Front Seat III-11Initiatives by Regulatory Bodies Favor Generics III-11Initiatives to Cut Spending on Antipsychotics III-11Antipsychotics Use in Nursing Homes Raises Concern III-12Rising Antipsychotic Use among Children - A Cause ofConcern III-13Table 37: US Antipsychotics Market (2010): PercentageShare Breakdown of Number of Prescriptions (to Children)by Practitioner - Psychiatrist, Pediatrics, NursePractitioners, General Physician, and Others (includescorresponding Graph/Chart) III-14Product Launches III-14Strategic Corporate Developments III-18Key Players III-29B.Market Analytics III-37Table 38: US Recent Past, Current & Future Analysis for CNSTherapeutics by Product Group - Anti-Alzheimer's,Anti-Parkinson's, Anti-Epilepsy, Pain Management,Anti-Psychotics, Anti-Depressants and Other MarketsIndependently Analyzed with Annual Sales Figures in US$Million for Years 2010 through 2018 (includes correspondingGraph/Chart) III-37
Table 39: US Historic Review for CNS Therapeutics by ProductGroup - Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy,Pain Management, Anti-Psychotics, Anti-Depressants and OtherMarkets Independently Analyzed with Annual Sales Figures inUS$ Million for Years 2004 through 2009 (includescorresponding Graph/Chart) III-38
Table 40: US 15-Year Perspective for CNS Therapeutics byProduct Group - Percentage Breakdown of Dollar Sales forAnti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, PainManagement, Anti-Psychotics, Anti-Depressants and OtherMarkets for 2004, 2012 & 2018 (includes correspondingGraph/Chart) III-39
2. CANADA III-40A.Market Analysis III-40Current & Future Analysis III-40CNS Diseases: Facts & Figures III-40Product Launches III-40Strategic Corporate Developments III-41B.Market Analytics III-43Table 41: Canadian Recent Past, Current & Future Analysisfor CNS Therapeutics by Product Group - Anti-Alzheimer's,Anti-Parkinson's, Anti-Epilepsy, Pain Management,Anti-Psychotics, Anti-Depressants and Other MarketsIndependently Analyzed with Annual Sales Figures in US$Million for Years 2010 through 2018 (includes correspondingGraph/Chart) III-43
Table 42: Canadian Historic Review for CNS Therapeutics byProduct Group - Anti-Alzheimer's, Anti-Parkinson's,Anti-Epilepsy, Pain Management, Anti-Psychotics,Anti-Depressants and Other Markets Independently Analyzedwith Annual Sales Figures in US$ Million for Years 2004through 2009 (includes corresponding Graph/Chart) III-44
Table 43: Canadian 15-Year Perspective for CNS Therapeuticsby Product Group - Percentage Breakdown of Dollar Sales forAnti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, PainManagement, Anti-Psychotics, Anti-Depressants and OtherMarkets for 2004, 2012 & 2018 (includes correspondingGraph/Chart) III-45
3. EUROPE III-46A.Market Analysis III-46Current & Future Analysis III-46Pain Management Market III-46Branded Drugs Feel the Heat of Generic Erosion III-46Uncertain Future of New Drug Development III-46Anti-Psychotics Market III-47An Overview III-47Demand for Antipsychotics for Bipolar Disorder Upbeat III-48Table 44: European Atypical Antipsychotics Market (BipolarDisorder) (2011): Percentage Share Breakdown of ValueSales by Seroquel, Abilify, Zyprexa, Geodon, and Others(includes corresponding Graph/Chart) III-48Generics to Witness Growth in Bipolar Disorder TherapeuticsMarket III-48Manufacturers Focus on New Drug Formulations III-49Clinical Pipeline III-49Product Launches III-49Strategic Corporate Developments III-50B.Market Analytics III-53Table 45: European Recent Past, Current & Future Analysisfor CNS Therapeutics by Geographic Region - France, Germany,Italy, UK, Spain and Rest of Europe Markets IndependentlyAnalyzed with Annual Sales in US$ Million for Years 2010through 2018 (includes corresponding Graph/Chart) III-53
Table 46: European Historic Review for CNS Therapeutics byGeographic Region - France, Germany, Italy, UK, Spain, andRest of Europe Markets Independently Analyzed with AnnualSales in US$ Million for Years 2004 through 2009 (includescorresponding Graph/Chart) III-54
Table 47: European Recent Past, Current & Future Analysisfor CNS Therapeutics by Product Group - Anti-Alzheimer's,Anti-Parkinson's, Anti-Epilepsy, Pain Management,Anti-Psychotics, Anti-Depressants and Other MarketsIndependently Analyzed with Annual Sales Figures in US$Million for Years 2010 through 2018 (includes correspondingGraph/Chart) III-55
Table 48: European Historic Review for CNS Therapeutics byProduct Group - Anti-Alzheimer's, Anti-Parkinson's,Anti-Epilepsy, Pain Management, Anti-Psychotics,Anti-Depressants and Other Markets Independently Analyzedwith Annual Sales Figures in US$ Million for Years 2004through 2009 (includes corresponding Graph/Chart) III-56
Table 49: European 15-Year Perspective for CNS Therapeuticsby Geographic Region - Percentage Breakdown of Value Salesfor France, Germany, Italy, UK, Spain, and Rest of EuropeMarkets for Years 2004, 2012 and 2018 (includescorresponding Graph/Chart) III-57
Table 50: European 15-Year Perspective for CNS Therapeuticsby Product Group - Percentage Breakdown of Dollar Sales forAnti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, PainManagement, Anti-Psychotics, Anti-Depressants and OtherMarkets for 2004, 2012 & 2018 (includes correspondingGraph/Chart) III-58
3a. FRANCE III-59A.Market Analysis III-59Current & Future Analysis III-59Product Launch III-59Sanofi S.A - A Key Player III-59B.Market Analytics III-61Table 51: French Recent Past, Current & Future Analysis forCNS Therapeutics by Product Group - Anti-Alzheimer's,Anti-Parkinson's, Anti-Epilepsy, Pain Management,Anti-Psychotics, Anti-Depressants and Other MarketsIndependently Analyzed with Annual Sales Figures in US$Million for Years 2010 through 2018 (includes correspondingGraph/Chart) III-61
Table 52: French Historic Review for CNS Therapeutics byProduct Group - Anti-Alzheimer's, Anti-Parkinson's,Anti-Epilepsy, Pain Management, Anti-Psychotics,Anti-Depressants and Other Markets Independently Analyzedwith Annual Sales Figures in US$ Million for Years 2004through 2009 (includes corresponding Graph/Chart) III-62
Table 53: French 15-Year Perspective for CNS Therapeutics byProduct Group - Percentage Breakdown of Dollar Sales forAnti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, PainManagement, Anti-Psychotics, Anti-Depressants and OtherMarkets for 2004, 2012 & 2018 (includes correspondingGraph/Chart) III-63
3b. GERMANY III-64A.Market Analysis III-64Current & Future Analysis III-64Boehringer Ingelheim GmbH - A Key Player III-64B.Market Analytics III-65Table 54: German Recent Past, Current & Future Analysis forCNS Therapeutics by Product Group - Anti-Alzheimer's,Anti-Parkinson's, Anti-Epilepsy, Pain Management,Anti-Psychotics, Anti-Depressants and Other MarketsIndependently Analyzed with Annual Sales Figures in US$Million for Years 2010 through 2018 (includes correspondingGraph/Chart) III-65
Table 55: German Historic Review for CNS Therapeutics byProduct Group - Anti-Alzheimer's, Anti-Parkinson's,Anti-Epilepsy, Pain Management, Anti-Psychotics,Anti-Depressants and Other Markets Independently Analyzedwith Annual Sales Figures in US$ Million for Years 2004through 2009 (includes corresponding Graph/Chart) III-66
Table 56: German 15-Year Perspective for CNS Therapeutics byProduct Group - Percentage Breakdown of Dollar Sales forAnti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, PainManagement, Anti-Psychotics, Anti-Depressants and OtherMarkets for 2004, 2012 & 2018 (includes correspondingGraph/Chart) III-67
3c. ITALY III-68A.Market Analysis III-68Current & Future Analysis III-68Market Snapshots III-68Strategic Corporate Development III-68B.Market Analytics III-69Table 57: Italian Recent Past, Current & Future Analysis forCNS Therapeutics by Product Group - Anti-Alzheimer's,Anti-Parkinson's, Anti-Epilepsy, Pain Management,Anti-Psychotics, Anti-Depressants and Other MarketsIndependently Analyzed with Annual Sales Figures in US$Million for Years 2010 through 2018 (includes correspondingGraph/Chart) III-69
Table 58: Italian Historic Review for CNS Therapeutics byProduct Group - Anti-Alzheimer's, Anti-Parkinson's,Anti-Epilepsy, Pain Management, Anti-Psychotics,Anti-Depressants and Other Markets Independently Analyzedwith Annual Sales Figures in US$ Million for Years 2004through 2009 (includes corresponding Graph/Chart) III-70
Table 59: Italian 15-Year Perspective for CNS Therapeuticsby Product Group - Percentage Breakdown of Dollar Sales forAnti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, PainManagement, Anti-Psychotics, Anti-Depressants and OtherMarkets for 2004, 2012 & 2018 (includes correspondingGraph/Chart) III-71
3d. THE UNITED KINGDOM III-72A.Market Analysis III-72Current & Future Analysis III-72NICE Recommendations on CNS Therapeutics III-72Product Launches III-72Strategic Corporate Developments III-75Key Players III-76B.Market Analytics III-80Table 60: UK Recent Past, Current & Future Analysis for CNSTherapeutics by Product Group - Anti-Alzheimer's,Anti-Parkinson's, Anti-Epilepsy, Pain Management,Anti-Psychotics, Anti-Depressants and Other MarketsIndependently Analyzed with Annual Sales Figures in US$Million for Years 2010 through 2018 (includes correspondingGraph/Chart) III-80
Table 61: UK Historic Review for CNS Therapeutics by ProductGroup - Anti-Alzheimer's, Anti-Parkinson's, Anti-E
To order this report:Therapy Industry: Global CNS Therapeutics Industry
__________________________Contact Clare: [email protected] US:(339) 368 6001 Intl:+1 339 368 6001
SOURCE Reportlinker
Advertisement
Global CNS Therapeutics Industryhttp://www.reportlinker.com/p01139068/Global-CNS-Therapeutics-Industry.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Therapy
Advertisement
This report analyzes the worldwide markets for CNS Therapeutics in US$ Million by the following Product Groups: Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management (includes Migraine, Nociceptive and neuropathic pain), Anti-Psychotics, Anti-Depressants, and Others (includes Multiple Sclerosis, Insomnia and ADHD). The report provides separate comprehensive analytics for the US, Canada, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2010 through 2018.
The report profiles 127 companies including many key and niche players such as AbbVie Inc., Alkermes Plc, Amneal Pharmaceuticals, LLC, Aspen Pharmacare Holdings Limited, AstraZeneca Plc, BEACON Pharmaceutical Limited, BIAL Group, Boehringer Ingelheim GmbH, Bristol-Myers Squibb, Dainippon Sumitomo Pharma Co., Ltd., Eisai Co., Ltd., Elan Corporation Plc, Eli Lilly and Co., F. Hoffmann-La Roche Ltd., Fabre-Kramer Pharmaceuticals, Inc., Forest Laboratories, Inc., GlaxoSmithKline, H. Lundbeck A/S, Johnson & Johnson, Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Neurocrine Biosciences, Inc., Novartis AG, Otsuka Pharmaceutical Co., Ltd., Pfizer, Inc., Sanofi S.A, Shire Plc, Sunovion Pharmaceuticals, Inc., Takeda Pharmaceutical Co., Ltd., Teva Pharmaceutical Industries Ltd., and UCB Group.
Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain.
I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONSStudy Reliability and Reporting Limitations I-1Disclaimers I-2Data Interpretation & Reporting Level I-2Quantitative Techniques & Analytics I-3Product Definitions and Scope of Study I-3CNS Disorders I-3Anti-Alzheimer's Drugs I-3Anti-Parkinson's Drugs I-4Anti-Epilepsy Drugs I-4Pain Management Drugs I-4Anti-Psychotics Drugs I-5Bipolar disorder I-5Schizophrenia I-5Anti-Depressants Drugs I-5Others I-6Attention Deficit Hyperactivity Disorder I-6Multiple Sclerosis I-6Insomnia I-6Restless Legs Syndrome I-7Anxiety I-7
II. EXECUTIVE SUMMARY
1. INDUSTRY OVERVIEW II-1CNS Diseases, Treatment & Therapeutics: A Primer II-1CNS Drugs: The Next Big Thing in the Healthcare Industry II-1Major Growth Drivers in a Capsule II-2Noteworthy Market Trends/Drivers & Issues II-2Aging Population: A Key Demand Propellant II-2Table 1: Percentage Share Breakdown of Global Population byAge Group, Worldwide: 2025 (includes correspondingGraph/Chart) II-3
Table 2: World Population of People Aged 65+ Years (InMillion) for Years 2012, 2020 & 2050 (includes correspondingGraph/Chart) II-4Developments in CNS Drug Delivery Technologies Bode Well forthe CNS Drugs Market II-4Understanding of BBB Cell Biology & Its Positive Impact onEpilepsy Drugs: A Case-in-Point II-4Healthcare Cost Rationing & Government Caps Challenge BrandedCNS Drugs II-5Slew of Imminent Patent Expiries to Exert Downward Pressureon the CNS Drugs Market II-6Patent Expiries of Leading CNS Drugs: 2008-2022 II-7Branded Generic CNS Drugs: A Key Revenue Spinner in EmergingCountries II-8Focused R&D Efforts: Need of the Hour II-8Need Factor in the Epilepsy Market: A Case-In-Point II-8Pharma Companies: Seeking New Tools to Offset Pressure onDrug Pipelines II-9Huge Unmet Medical Needs Underpin Market Potential II-10A Special Focus on the Unmet Needs in Epilepsy II-10Awareness Campaigns Launched by Pharma Companies to Benefitthe Market II-11
2. MARKET OVERVIEW & TRENDS ACROSS CNS THERAPEUTIC AREAS II-12Anti-Epilepsy II-12Market Overview II-12Table 3: Global Sales of Select Leading Anti-Epilepsy DrugBrands In US$ Million for the Year 2011 (includescorresponding Graph/Chart) II-13A Peek into Select Epilepsy Drugs Currently Available in theMarketplace II-13A Peek Into Few of the Popular Anti-Epileptic Drugs andTheir Mechanism of Action II-15Higher Incidences in Developing Countries II-15Abounding Potential for NCEs II-15A Peek into Select Epilepsy Drugs in Clinical Development Asof the Year 2012 II-16A Peek into Select Anti-Epileptic Drugs Approved in theYears 2011 & 2012 II-17Pregnancy Safe Anti-Epileptic Drugs: Need of the Hour II-17CNS Pain Management II-17Market Overview II-17Combination Therapies Gain Prominence II-18Migraine Market Offers Growth Opportunities to ProphylaxisProducts II-18Neuropathic Pain Management: A Potential Laden Market II-19Strong Product Pipeline to Benefit the Neuropathic PainManagement Market II-19Anti-Alzheimer's II-20Market Overview II-20Anti-Parkinson's II-20Market Overview II-20Anti-Depressants II-21Market Overview II-21Attention Deficit Hyperactivity Disorder (ADHD) II-21Market Overview II-21Anti-Psychotics II-22Market Overview II-22Prevalence of Schizophrenia and Bipolar Disorders:Statistical Snippets II-22Second Generation Antipsychotics Beset With Safety Issues II-23Companies Focus on Next Generation Products To Deflect theHeat of Competition II-23Table 4: World Antipsychotics Market (2011): Sales ofLeading Drug Brands - Seroquel IR, Seroquel XR, Abilify,Zyprexa & Zyprexa Relprevv, Risperdal & Risperdal Consta,Geodon, and Invega & Invega Sustenna (In US$ Million)(includes corresponding Graph/Chart) II-24A Peek into Anti-Psychotic Drugs in Late-Stage ClinicalDevelopment As of 2012 II-25
3. CHANGING HEALTHCARE INDUSTRY IN EUROPE & THE UNITED STATES II-26Healthcare Economics, the Eurozone Crisis & Changing Role ofthe Government in Europe's Healthcare System II-26Impact of Europe's Rationing Healthcare System On CNS Drugs II-27Impact On Pharma Companies in Europe II-28Outlook for CNS Therapeutics in the United States in Light ofthe Fiscal Cliff II-30
4. PRODUCT OVERVIEW II-32Definition II-32Central Nervous System II-32Mortality Threat of CNS Disorders II-32Science of NMDA Receptors and its Disease Significance II-32Major CNS Disorders: II-33Alzheimer's Disease II-33Alzheimer's Affect on Brain II-33Causes for Alzheimer's II-34Who Are at Risk? II-34Prevalence of Alzheimer's Disease II-35Diagnosis of Alzheimer's II-35Treatment for Alzheimer's II-35Parkinson's Disease II-36Prevalence of Parkinson's II-36Symptom of Parkinson's II-36Causes of Parkinson's II-37Parkinson's Diagnosis II-37Therapies for Parkinson's II-38Surgery: The Last Option II-38Epilepsy II-38Causes of Epilepsy II-38Symptoms of Epilepsy II-39Types of Epilepsy and Epileptic Seizures II-39Preventive Measures II-40Treatment Options for Epilepsy Patients II-40Treatment Options Available for Epilepsy Patients II-41Epilepsy Drug Treatment Paradigm II-41Pain Management II-41Debilitating Effects of Pain II-42Types of Pain II-42Acute Pain II-42Chronic Pain II-42Migraine II-43Neuropathic Pain II-43Nociceptive Pain II-43Pain Management Therapies II-43Bipolar Disorder II-44Symptoms of Bipolar Disorder II-44Mood Episode - A Major Symptom II-44Manic Episode Vs Depressive Episode II-45Causes of Bipolar Disorder II-45Types of Bipolar Disorder II-46Co-morbidities of Bipolar Disorder II-46Schizophrenia II-46Prevalence by Gender II-47Symptoms of Schizophrenia II-47Causes of Schizophrenia II-48Therapies for Bipolar Disorder & Schizophrenia II-48Mood Stabilizing Agents II-49Antidepressants II-49Antipsychotic Drugs II-49Indications of Antipsychotics II-50An Effective Adjunctive Therapy II-50Off-label Uses II-50Efficacy - Marred by Lack of Evidence Base II-50Types of Antipsychotics II-51Difference between Typical and Atypical II-51Atypical Antipsychotics Up Against Typicals II-51Side Effects of Antipsychotics II-52Symptoms of Antipsychotics Withdrawal II-53Controversies Surrounding Antipsychotics II-54Prohibited Practices II-54Antipsychotics in Pregnant Women II-54Depression II-55Prevalence of Depression II-55Causes of Depression II-55Types of Depressive Disorders II-56Available Treatment II-56Tricyclic Antidepressants II-56Monoamine Oxidase Inhibitors II-56Lithium Salts II-56Working of Antidepressants II-57Ranking of Antidepressants in Terms of Efficacy II-57Types of Antidepressants II-57NMDA Receptor Antagonists II-57NMDA Receptor (NMDAR) II-57NMDA Receptor Agonists II-58Acetylcholinesterase Inhibitors II-58Selective Serotonin Reuptake Inhibitors (SSRIs) II-58Workings of SSRIs II-59Safety Levels of SSRI Drugs II-59Adverse Effects of SSRI II-59Serotonin Noradrenaline Reuptake Inhibitors (SNRIs) II-59Others Common CNS Disorders II-60Attention Deficit Hyperactivity Disorder II-60Consequences of ADHD II-60What Leads to ADHD? II-60Treating ADHD II-61Multiple Sclerosis (MS) II-61Types of Multiple Sclerosis II-61Prevalence of MS II-62Causes of MS II-62Myths Surrounding Multiple Sclerosis II-62Symptoms of MS II-62Diagnosis of MS II-62Therapies for MS II-63Insomnia II-63Prevalence of Insomnia II-63Therapies for Insomnia II-63Restless Legs Syndrome II-63Anxiety II-64
5. REVIEW OF SELECT CNS DRUGS II-65Anti-Alzheimer's Drugs II-65Aricept II-65Exelon II-65Reminyl II-65Ebixa II-65Namenda II-65Anti-Parkinson's Drugs II-66Levodopa II-66Dopamine Agonists II-66Mirapex II-66Requip II-66Anti-Epilepsy Drugs II-66Vimpat® II-67Keppra® II-67Lamictal II-68Tegretol® II-68Sabril® II-68Perampanel II-68Zonegran® II-68Topamax® II-69Trileptal® II-69Neurontin® II-69Lyrica® II-69Depakine® II-69Pain Management II-70Flupirtine II-70Lyrica® II-70Oxycodone II-70Nucynta ER II-70Cymbalta® II-70Metabotropic Glutamate Receptors (mGluRs) II-70Anti-Psychotic Drugs II-71Zyprexa II-71Seroquel II-71Abilify II-72Clozaril II-72Risperdal II-72Risperdal® Consta® II-72Geodon II-73Invega Sustenna II-73Saphris II-73Latuda II-73Antidepressants Drugs II-74Zoloft (Sertraline) II-74Prozac (Fluoxetine) II-74Effexor (Venlafaxine) II-74Paxil II-74Wellbutrin (Bupropion) II-74Attention Deficit Hyperactivity Disorder (ADHD) II-75Concerta II-75Strattera II-75Adderall II-75Insomnia II-75Zolpidem II-76Eszopiclone II-76
6. RESEARCH & DEVELOPMENT II-77Research Finds Higher Diabetes Risk among Antipsychotic-Treated Patients II-77Zonisamide is Effective in Epilepsy Prevention in Children II-77Latuda Effective in Bipolar I Depression Treatment II-77Cariprazine Effective in Bipolar I Disorder Treatment II-78Alkermes Initiates Phase III Clinical Trials of InvegaSustenna II-78Antipsychotics Increase Mortality Risk in Dementia Patients II-78Potential Antipsychotic Drug Fails in Clinical Study II-79Pfizer Discontinues Clinical Trial of Lyrica Capsules CV II-79Cariprazine Shows Efficacy in Acute Schizophrenia Treatment II-79Prevention of Neuropathic Pain through Saxitoxin DexamethasoneLiposomes II-79Perampanel Effective in Reducing Epileptic Seizures II-80Targacept Initiates Trials of its Novel Schizophrenia Drug II-80Vertex Develops VX-765 for Epilepsy II-80ALKS 9070 Effective in Treatment of Schizophrenia II-80Lyrica Effective in Central Neuropathic Pain Following SpinalCord Injury II-81UCB's Vimpat Reduces Partial-Onset Seizure II-81Eisai Announces Encouraging Results for Perampanel II-81
7. PRODUCT INTRODUCTIONS/INNOVATIONS II-82Eisai Launches Fycompa II-82Dr Reddy's Unveils Generic Zyprexa in the US II-82Eisai Europe Launches Zebinix® Eslicarbazepine Acetate II-82Sun Pharma, Lupin and Dr Reddy's Introduce GenericSchizophrenia Drug II-82Mylan Launches Levetiracetam in Sodium Chloride Injection II-82Dr. Reddy's Laboratories Introduces Generic Antipsychotic Drug II-83Eisai to Unveil Fycompa Antiepileptic Agent II-83H. Lundbeck Introduces Sycrest II-83GW Pharmaceuticals to Develop Cannabis-Based EpilepticTreatment II-83Sun Pharmaceutical Unveils Zyprexa Zydis II-84Eisai to Unveil Zonegran Drug Treatment in Russia II-84Teva Pharmaceutical Industries Introduces Quetiapine andQuetiapine XL II-84Eisai and Nobelpharma to Introduce Fostoin AnticonvulsantAgent II-84Janssen Pharmaceuticals Receives Approval for Updated ProductLabeling II-84H Lundbeck Introduces Onfi Anti-Epileptic Drug in US II-85Amneal Pharmaceuticals Unveils Felbamate Generic Anti-Epileptic Drug II-85Teva UK Unveils Generic Olanzapine for Schizophrenia II-85Mylan Pharmaceuticals Unveils Divalproex Sodium Capsules USP II-86Actavis Introduces Generic Olanzapine Tablets II-86GlaxoSmithKline Introduces Trobalt® Anti-Epileptic Drug II-86Alkermes Launches Phase III Clinical Trial for Drug CandidateALKS 9070 II-86BIAL and Eisai Unveil Zebinix® Drug in Spain II-86Amneal Launches AA-Rated Generic Oral Drugs II-86Orexo Introduces Analgesic Drug Abstral II-87MSN Laboratories Unveils Tapal for Pain Management II-87CNS Pain Management Company Introduces Palexia® SR II-87Glenmark Genetics Introduces New Formulations for PainManagement II-87Vanda Pharmaceuticals Introduces Fanapt for Schizophrenia II-88Roche to Develop RG-1678 Schizophrenia Drug II-88H. Lundbeck and King's College London Launch Academic-IndustryCollaboration Project II-88Alkermes Develops LinkeRx™ technology Platform for CNSTherapies II-89Novartis Introduces Fanapt Schizophrenia Drug II-89Axxess Pharma Signs Agreement to Market Fortex II-89Nutra Pharma Unveils Cobroxin in CVS II-89
8. RECENT INDUSTRY ACTIVITY II-90UCB and Otsuka Pharmaceuticals to Develop Anti-Epileptic Drugs II-90Sunovion Files for Expanded Use of Latuda® II-90Eisai Receives Manufacturing License in the UK II-90Dainippon Sumitomo and Takeda Receive Acceptance from the EMA II-90Lupin Receives FDA Approval to Market Anti-Epileptic Drugs II-91Dainippon Sumitomo Inks an Agreement with Takeda II-91Sanofi and Alfresa Pharma Ink Agreement to Develop Vigabatrin II-91Sunovion Files two sNDAs for Latuda® II-91Prasco Laboratories Inks Agreement with Shire II-92Otsuka Files for Additional Indication for Abilify® II-92Aspen Global to Take Over Drug Portfolio of GlaxoSmithKline II-92Par Pharmaceutical and Handa Pharmaceuticals Ink LicensingAgreement II-92Upsher-Smith Laboratories Takes Over Proximagen Group II-92Mylan Pharmaceuticals Receives FDA Approval for LithiumCarbonate Extended-release Tablets USP II-93Supernus Obtains Approval for Oxtellar XR Anti-Epilepsy Drug II-93FDA Denies Antipsychotic Drug from Otsuka and Lundbeck II-93Eisai Receives Approval for Fycompa Drug II-93Forest Laboratories Submits NDA for Cariprazine II-94Lupin Pharmaceuticals Obtains Approval for LevetiracetamGeneric Drug II-94Johnson & Johnson Pays Fine for Illegal Marketing II-94UCB Discloses Epilepsy Drug Trial Results II-94GSK Agrees to Pay Criminal Fine for Illegal Promotion II-94GlaxoSmithKline Obtains Marketing Approval for Trobalt™ II-94Novartis Discontinues Development of Fanapt II-95Qualitest Pharmaceuticals Obtains FDA Approval forLevetiracetam Tablets II-95Eisai Europe Obtains Approval for Zonegran® Anti-EpilepticAgent II-95Eisai Obtains Approval for Zonegran® II-95Glenmark Generics Obtains FDA Approval for Lamotrigine II-96Mylan Obtains FDA Approval for Levetiracetam Extended-ReleaseTablets II-96Forest Laboratories Enters into Broad Strategic Alliance withmoksha8 II-96moksha8 Extends License Agreement with Watson Pharmaceuticals II-96Paladin Labs and QRxPharma Sign Licensing Agreement II-97Mallinckrodt Acquires CNS Therapeutics II-97Neurodyn Takes Over NeuroQuest II-97Zogenix Inks Exclusive Co-Promotion Agreement withMallinckrodt II-98Omron Healthcare Unveils Omron electroTHERAPY Pain Relief Unit II-98Watson Pharmaceuticals Rolls Out REPREXAINTM CIII II-99INSYS Therapeutics Launches SUBSYS™ Dosage Form for BTCPTreatment II-99Actavis Signs Agreement with QRxPharma to Market MOXDUO® IR II-99Mallinckrodt Receives FDA Approval for EXALGO® Tablet II-99Biostar Pharmaceuticals Obtains Army New Drug Certificate forZushima Analgesic Spray II-100Pfizer Receives FDA Approval for Lyrica® Capsules II-100Teva Acquires Cephalon II-100Eisai Files for Expanded Use of Zonegran II-100Johnson & Johnson Recalls Schizophrenia Drug II-101Intellipharmaceutics Files for NDA Approval for Lamictal XRGeneric Version II-101BioLineRx Receives New Patent Protection for SchizophreniaDrug II-101Aurobindo Pharmaceuticals Obtains FDA Approval for GabapentinTablets II-101Zogenix Acquires Rights to Utilize Durect's Technology forRelday II-101Unichem Obtains FDA Approval for Lamotrigine Tablets II-102BioLineRx Signs Agreement with Cypress Bioscience II-102Eisai Obtains Approval from Health Canada for Banzel II-102Alkermes Acquires Elan Drug Technologies II-102Eisai Obtains FDA Approval for Oral Suspension of Banzel II-103Pfizer Acquires Icagen II-103Health Canada Grants Approval for Abilify® to TreatSchizophrenia in Adolescents II-103GlaxoSmithKline Receives Approval for Rotavirus Vaccine andLamictal Tablets II-103Janssen Obtains Approval for Xeplion from European Commission II-104Janssen-Cilag Receives FDA Approval for INVEGA® II-104Janssen-Cilag International Secures EC Approval for INVEGA II-104Actavis Enters into Letter of Intent with QRxPharma II-104DSM Pharmaceutical and QRxPharma Ink Manufacturing and SupplyAgreement II-105UCB Takes Over Key Pharmaceutical Assets of LectusTherapeutics II-105Teva Pharmaceutical Industries Acquires Cephalon II-106Biotie Therapies Takes Over Newron Pharmaceuticals II-106RaQualia Pharma Enters into Collaboration with Eli Lilly II-106Elder Pharmaceuticals to Launch New Therapeutic Products II-107Lupin Pharmaceuticals Obtains FDA Approval for Tramadol ERTablets II-107Envoy Therapeutics and Takeda Pharmaceutical Form ResearchAlliance II-107Ranbaxy Recalls Anti-Epileptic Drug from UK II-107H. Lundbeck Inks Global Commercialization Agreement with Merck II-107Medco Research Institute to Form Alliance with SureGene II-108Forest Labs and Gruenenthal Sign License Agreement II-108Endo Pharmaceuticals Holdings Acquires QualitestPharmaceuticals II-108IntelGenx Inks an Agreement with PediPharm II-109Insys Therapeutics Merges with NeoPharm II-109HepaLife Technologies Collaborates with Jeiven Pharmaceutical II-109Pfizer to Take Over King Pharmaceuticals II-110The Apothecary Shops Takes Over Greater Sacramento SpecialtyPharmacy II-110NsGene and Biogen Idec Ink New Commercialization and LicenseAgreement II-110Xanodyne Pharmaceuticals Inks Co-Promotion Agreement withFerring Pharmaceuticals II-111QRxPharma Enters into Strategic Alliance with China AoxingPharmaceutical II-111Pfizer Japan Obtains New Indication Approval for Lyrica®Capsules II-111Eli Lilly and Company Receives FDA Approval for Cymbalta II-112
9. FOCUS ON SELECT GLOBAL PLAYERS II-113AbbVie Inc (USA) II-113Alkermes Plc (Ireland) II-113Amneal Pharmaceuticals, LLC (USA) II-114Aspen Pharmacare Holdings Limited (South Africa) II-115AstraZeneca Plc (UK) II-115BEACON Pharmaceutical Limited (UK) II-116BIAL Group (Portugal) II-116Boehringer Ingelheim GmbH (Germany) II-116Bristol-Myers Squibb (USA) II-117Dainippon Sumitomo Pharma Co., Ltd. (Japan) II-118Eisai Co., Ltd. (Japan) II-119Elan Corporation Plc (Ireland) II-120Eli Lilly and Co. (USA) II-120F. Hoffmann-La Roche Ltd. (Switzerland) II-121Fabre-Kramer Pharmaceuticals, Inc. (USA) II-121Forest Laboratories, Inc. (USA) II-122GlaxoSmithKline (UK) II-122H. Lundbeck A/S (Denmark) II-123Johnson & Johnson (USA) II-124Janssen Pharmaceuticals, Inc. (USA) II-125Merck & Co., Inc. (USA) II-125Neurocrine Biosciences, Inc. (USA) II-125Novartis AG (Switzerland) II-126Otsuka Pharmaceutical Co., Ltd. (Japan) II-127Pfizer, Inc. (USA) II-127Sanofi S.A (France) II-128Shire Plc (UK) II-130Sunovion Pharmaceuticals, Inc. (USA) II-130Takeda Pharmaceutical Co., Ltd. (Japan) II-130Teva Pharmaceutical Industries Ltd. (Israel) II-131UCB Group (Belgium) II-131
10. GLOBAL MARKET PERSPECTIVE II-133Table 5: World Recent Past, Current & Future Analysis for CNSTherapeutics by Geographic Region - US, Canada, Europe,Asia-Pacific, Latin America and Rest of World MarketsIndependently Analyzed by Annual Sales in US$ Million for theYears 2010 through 2018 (includes corresponding Graph/Chart) II-133
Table 6: World Historic Review for CNS Therapeutics byGeographic Region - US, Canada, Europe, Asia-Pacific, LatinAmerica and Rest of World Markets Independently Analyzed byAnnual Sales in US$ Million for the Years 2004 through 2009(includes corresponding Graph/Chart) II-134
Table 7: World 15-Year Perspective for CNS Therapeutics byGeographic Region - Percentage Breakdown of Value Sales forUS, Canada, Europe, Asia-Pacific, Latin America and Rest ofWorld Markets for the Years 2004, 2012 and 2018 (includescorresponding Graph/Chart) II-135
Table 8: World Recent Past, Current & Future Analysis forAnti-Alzheimer's by Geographic Region - US, Canada, Europe,Asia-Pacific, Latin America and Rest of World MarketsIndependently Analyzed by Annual Sales in US$ Million for theYears 2010 through 2018 (includes corresponding Graph/Chart) II-136
Table 9: World Historic Review for Anti-Alzheimer's byGeographic Region - US, Canada, Europe, Asia-Pacific, LatinAmerica and Rest of World Markets Independently Analyzed byAnnual Sales in US$ Million for the Years 2004 through 2009(includes corresponding Graph/Chart) II-137
Table 10: World 15-Year Perspective for Anti-Alzheimer's byGeographic Region - Percentage Breakdown of Value Sales forUS, Canada, Europe, Asia-Pacific, Latin America and Rest ofWorld Markets for the Years 2004, 2012 and 2018 (includescorresponding Graph/Chart) II-138
Table 11: World Recent Past, Current & Future Analysis forAnti-Parkinson's by Geographic Region - US, Canada, Europe,Asia-Pacific, Latin America and Rest of World MarketsIndependently Analyzed by Annual Sales in US$ Million for theYears 2010 through 2018 (includes corresponding Graph/Chart) II-139
Table 12: World Historic Review for Anti-Parkinson's byGeographic Region - US, Canada, Europe, Asia-Pacific, LatinAmerica and Rest of World Markets Independently Analyzed byAnnual Sales in US$ Million for the Years 2004 through 2009(includes corresponding Graph/Chart) II-140
Table 13: World 15-Year Perspective for Anti-Parkinson's byGeographic Region - Percentage Breakdown of Value Sales forUS, Canada, Europe, Asia-Pacific, Latin America and Rest ofWorld Markets for the Years 2004, 2012 and 2018 (includescorresponding Graph/Chart) II-141
Table 14: World Recent Past, Current & Future Analysis forAnti-Epilepsy by Geographic Region - US, Canada, Europe,Asia-Pacific, Latin America and Rest of World MarketsIndependently Analyzed by Annual Sales in US$ Million for theYears 2010 through 2018 (includes corresponding Graph/Chart) II-142
Table 15: World Historic Review for Anti-Epilepsy byGeographic Region - US, Canada, Europe, Asia-Pacific, LatinAmerica and Rest of World Markets Independently Analyzed byAnnual Sales in US$ Million for the Years 2004 through 2009(includes corresponding Graph/Chart) II-143
Table 16: World 15-Year Perspective for Anti-Epilepsy byGeographic Region - Percentage Breakdown of Value Sales forUS, Canada, Europe, Asia-Pacific, Latin America and Rest ofWorld Markets for the Years 2004, 2012 and 2018 (includescorresponding Graph/Chart) II-144
Table 17: World Recent Past, Current & Future Analysis forPain Management by Geographic Region - US, Canada, Europe,Asia-Pacific, Latin America and Rest of World MarketsIndependently Analyzed by Annual Sales in US$ Million for theYears 2010 through 2018 (includes corresponding Graph/Chart) II-145
Table 18: World Historic Review for Pain Management byGeographic Region - US, Canada, Europe, Asia-Pacific, LatinAmerica and Rest of World Markets Independently Analyzed byAnnual Sales in US$ Million for the Years 2004 through 2009(includes corresponding Graph/Chart) II-146
Table 19: World 15-Year Perspective for Pain Management byGeographic Region - Percentage Breakdown of Value Sales forUS, Canada, Europe, Asia-Pacific, Latin America and Rest ofWorld Markets for the Years 2004, 2012 and 2018 (includescorresponding Graph/Chart) II-147
Table 20: World Recent Past, Current & Future Analysis forAnti-Psychotics by Geographic Region - US, Canada, Europe,Asia-Pacific, Latin America and Rest of World MarketsIndependently Analyzed by Annual Sales in US$ Million for theYears 2010 through 2018 (includes corresponding Graph/Chart) II-148
Table 21: World Historic Review for Anti-Psychotics byGeographic Region - US, Canada, Europe, Asia-Pacific, LatinAmerica and Rest of World Markets Independently Analyzed byAnnual Sales in US$ Million for the Years 2004 through 2009(includes corresponding Graph/Chart) II-149
Table 22: World 15-Year Perspective for Anti-Psychotics byGeographic Region - Percentage Breakdown of Value Sales forUS, Canada, Europe, Asia-Pacific, Latin America and Rest ofWorld Markets for the Years 2004, 2012 and 2018 (includescorresponding Graph/Chart) II-150
Table 23: World Recent Past, Current & Future Analysis forAnti-Depressants by Geographic Region - US, Canada, Europe,Asia-Pacific, Latin America and Rest of World MarketsIndependently Analyzed by Annual Sales in US$ Million for theYears 2010 through 2018 (includes corresponding Graph/Chart) II-151
Table 24: World Historic Review for Anti-Depressants byGeographic Region - US, Canada, Europe, Asia-Pacific, LatinAmerica and Rest of World Markets Independently Analyzed byAnnual Sales in US$ Million for the Years 2004 through 2009(includes corresponding Graph/Chart) II-152
Table 25: World 15-Year Perspective for Anti-Depressants byGeographic Region - Percentage Breakdown of Value Sales forUS, Canada, Europe, Asia-Pacific, Latin America and Rest ofWorld Markets for the Years 2004, 2012 and 2018 (includescorresponding Graph/Chart) II-153
Table 26: World Recent Past, Current & Future Analysis forOthers by Geographic Region - US, Canada, Europe,Asia-Pacific, Latin America and Rest of World MarketsIndependently Analyzed by Annual Sales in US$ Million for theYears 2010 through 2018 (includes corresponding Graph/Chart) II-154
Table 27: World Historic Review for Others by GeographicRegion - US, Canada, Europe, Asia-Pacific, Latin America andRest of World Markets Independently Analyzed by Annual Salesin US$ Million for the Years 2004 through 2009 (includescorresponding Graph/Chart) II-155
Table 28: World 15-Year Perspective for Others by GeographicRegion - Percentage Breakdown of Value Sales for US, Canada,Europe, Asia-Pacific, Latin America and Rest of World Marketsfor the Years 2004, 2012 and 2018 (includes correspondingGraph/Chart) II-156
III. MARKET
1. THE UNITED STATES III-1A.Market Analysis III-1Current & Future Analysis III-1Market Overview III-1Focus on Select Markets III-1Alzheimer's Market III-1Anti-Epilepsy Market III-1Epilepsy - A Major Concern for Healthcare Industry III-1A Glance at Epilepsy Statistics III-2Anti-Epilepsy Drugs: Market Overview III-2Table 29: Number of Dispensed Prescriptions in the USAnti-Epileptic Drugs Market in Million (2007-2012)(includes corresponding Graph/Chart) III-3Epilepsy in Children III-3Growing Competition from Generics III-4Pain Management Market III-4Neuropathic Pain Market III-5Anti-Psychotic Drugs Market III-5Mental Illnesses - An Epidemiology III-5Facts & Figures III-5Table 30: Lifetime Prevalence (%) of Bipolar Disorder inthe US Population by Age Group (includes correspondingGraph/Chart) III-6Popular Antipsychotic Drugs in the US III-6Table 31: Sales of Select Anti-Psychotic Drugs in the US(2011) (In US$ Million) (includes correspondingGraph/Chart) III-7Anti-Psychotic Drugs by FDA Approved Age and Indicationin the US III-7Table 32: US Anti-Psychotic Drugs Market (2012):Percentage Breakdown of Value Sales by Indication -Bipolar Disorder, Schizophrenia, Major DepressiveDisorder, and Others (includes corresponding Graph/Chart) III-8
Table 33: US Antipsychotics Market (2012): PercentageShare Breakdown of Prescriptions by Indication - BipolarDisorder, Schizophrenia, Major Depressive Disorder,Anxiety, and Others (includes corresponding Graph/Chart) III-8
Table 34: Leading Brands in the US Antipsychotics Market(2011): Percentage Share Breakdown of Number ofPrescriptions by Seroquel, Abilify, Zyprexa, Geodon,Seroquel XR and Others (includes correspondingGraph/Chart) III-8
Table 35: Leading Antipsychotic Brands in the USSchizophrenia Market (2011): Percentage Share Breakdownof Number of Prescriptions by Seroquel, Abilify, Zyprexa,Geodon, Seroquel XR and Others (includes correspondingGraph/Chart) III-9Growth Dampeners III-9Surging Off-label Prescriptions III-9Advertising for Antipsychotics Acquires a Whole NewDimension III-10Table 36: Leading Brands in the US Antipsychotics Market(2011): Percentage Share Breakdown of PromotionalSpending by Abilify, Seroquel, Saphris, Geodon, Latuda,Invega, Zyprexa, and Others (includes correspondingGraph/Chart) III-10Illegal Marketing - A Cause of Concern for Governments III-10Generics Occupy Front Seat III-11Initiatives by Regulatory Bodies Favor Generics III-11Initiatives to Cut Spending on Antipsychotics III-11Antipsychotics Use in Nursing Homes Raises Concern III-12Rising Antipsychotic Use among Children - A Cause ofConcern III-13Table 37: US Antipsychotics Market (2010): PercentageShare Breakdown of Number of Prescriptions (to Children)by Practitioner - Psychiatrist, Pediatrics, NursePractitioners, General Physician, and Others (includescorresponding Graph/Chart) III-14Product Launches III-14Strategic Corporate Developments III-18Key Players III-29B.Market Analytics III-37Table 38: US Recent Past, Current & Future Analysis for CNSTherapeutics by Product Group - Anti-Alzheimer's,Anti-Parkinson's, Anti-Epilepsy, Pain Management,Anti-Psychotics, Anti-Depressants and Other MarketsIndependently Analyzed with Annual Sales Figures in US$Million for Years 2010 through 2018 (includes correspondingGraph/Chart) III-37
Table 39: US Historic Review for CNS Therapeutics by ProductGroup - Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy,Pain Management, Anti-Psychotics, Anti-Depressants and OtherMarkets Independently Analyzed with Annual Sales Figures inUS$ Million for Years 2004 through 2009 (includescorresponding Graph/Chart) III-38
Table 40: US 15-Year Perspective for CNS Therapeutics byProduct Group - Percentage Breakdown of Dollar Sales forAnti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, PainManagement, Anti-Psychotics, Anti-Depressants and OtherMarkets for 2004, 2012 & 2018 (includes correspondingGraph/Chart) III-39
2. CANADA III-40A.Market Analysis III-40Current & Future Analysis III-40CNS Diseases: Facts & Figures III-40Product Launches III-40Strategic Corporate Developments III-41B.Market Analytics III-43Table 41: Canadian Recent Past, Current & Future Analysisfor CNS Therapeutics by Product Group - Anti-Alzheimer's,Anti-Parkinson's, Anti-Epilepsy, Pain Management,Anti-Psychotics, Anti-Depressants and Other MarketsIndependently Analyzed with Annual Sales Figures in US$Million for Years 2010 through 2018 (includes correspondingGraph/Chart) III-43
Table 42: Canadian Historic Review for CNS Therapeutics byProduct Group - Anti-Alzheimer's, Anti-Parkinson's,Anti-Epilepsy, Pain Management, Anti-Psychotics,Anti-Depressants and Other Markets Independently Analyzedwith Annual Sales Figures in US$ Million for Years 2004through 2009 (includes corresponding Graph/Chart) III-44
Table 43: Canadian 15-Year Perspective for CNS Therapeuticsby Product Group - Percentage Breakdown of Dollar Sales forAnti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, PainManagement, Anti-Psychotics, Anti-Depressants and OtherMarkets for 2004, 2012 & 2018 (includes correspondingGraph/Chart) III-45
3. EUROPE III-46A.Market Analysis III-46Current & Future Analysis III-46Pain Management Market III-46Branded Drugs Feel the Heat of Generic Erosion III-46Uncertain Future of New Drug Development III-46Anti-Psychotics Market III-47An Overview III-47Demand for Antipsychotics for Bipolar Disorder Upbeat III-48Table 44: European Atypical Antipsychotics Market (BipolarDisorder) (2011): Percentage Share Breakdown of ValueSales by Seroquel, Abilify, Zyprexa, Geodon, and Others(includes corresponding Graph/Chart) III-48Generics to Witness Growth in Bipolar Disorder TherapeuticsMarket III-48Manufacturers Focus on New Drug Formulations III-49Clinical Pipeline III-49Product Launches III-49Strategic Corporate Developments III-50B.Market Analytics III-53Table 45: European Recent Past, Current & Future Analysisfor CNS Therapeutics by Geographic Region - France, Germany,Italy, UK, Spain and Rest of Europe Markets IndependentlyAnalyzed with Annual Sales in US$ Million for Years 2010through 2018 (includes corresponding Graph/Chart) III-53
Table 46: European Historic Review for CNS Therapeutics byGeographic Region - France, Germany, Italy, UK, Spain, andRest of Europe Markets Independently Analyzed with AnnualSales in US$ Million for Years 2004 through 2009 (includescorresponding Graph/Chart) III-54
Table 47: European Recent Past, Current & Future Analysisfor CNS Therapeutics by Product Group - Anti-Alzheimer's,Anti-Parkinson's, Anti-Epilepsy, Pain Management,Anti-Psychotics, Anti-Depressants and Other MarketsIndependently Analyzed with Annual Sales Figures in US$Million for Years 2010 through 2018 (includes correspondingGraph/Chart) III-55
Table 48: European Historic Review for CNS Therapeutics byProduct Group - Anti-Alzheimer's, Anti-Parkinson's,Anti-Epilepsy, Pain Management, Anti-Psychotics,Anti-Depressants and Other Markets Independently Analyzedwith Annual Sales Figures in US$ Million for Years 2004through 2009 (includes corresponding Graph/Chart) III-56
Table 49: European 15-Year Perspective for CNS Therapeuticsby Geographic Region - Percentage Breakdown of Value Salesfor France, Germany, Italy, UK, Spain, and Rest of EuropeMarkets for Years 2004, 2012 and 2018 (includescorresponding Graph/Chart) III-57
Table 50: European 15-Year Perspective for CNS Therapeuticsby Product Group - Percentage Breakdown of Dollar Sales forAnti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, PainManagement, Anti-Psychotics, Anti-Depressants and OtherMarkets for 2004, 2012 & 2018 (includes correspondingGraph/Chart) III-58
3a. FRANCE III-59A.Market Analysis III-59Current & Future Analysis III-59Product Launch III-59Sanofi S.A - A Key Player III-59B.Market Analytics III-61Table 51: French Recent Past, Current & Future Analysis forCNS Therapeutics by Product Group - Anti-Alzheimer's,Anti-Parkinson's, Anti-Epilepsy, Pain Management,Anti-Psychotics, Anti-Depressants and Other MarketsIndependently Analyzed with Annual Sales Figures in US$Million for Years 2010 through 2018 (includes correspondingGraph/Chart) III-61
Table 52: French Historic Review for CNS Therapeutics byProduct Group - Anti-Alzheimer's, Anti-Parkinson's,Anti-Epilepsy, Pain Management, Anti-Psychotics,Anti-Depressants and Other Markets Independently Analyzedwith Annual Sales Figures in US$ Million for Years 2004through 2009 (includes corresponding Graph/Chart) III-62
Table 53: French 15-Year Perspective for CNS Therapeutics byProduct Group - Percentage Breakdown of Dollar Sales forAnti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, PainManagement, Anti-Psychotics, Anti-Depressants and OtherMarkets for 2004, 2012 & 2018 (includes correspondingGraph/Chart) III-63
3b. GERMANY III-64A.Market Analysis III-64Current & Future Analysis III-64Boehringer Ingelheim GmbH - A Key Player III-64B.Market Analytics III-65Table 54: German Recent Past, Current & Future Analysis forCNS Therapeutics by Product Group - Anti-Alzheimer's,Anti-Parkinson's, Anti-Epilepsy, Pain Management,Anti-Psychotics, Anti-Depressants and Other MarketsIndependently Analyzed with Annual Sales Figures in US$Million for Years 2010 through 2018 (includes correspondingGraph/Chart) III-65
Table 55: German Historic Review for CNS Therapeutics byProduct Group - Anti-Alzheimer's, Anti-Parkinson's,Anti-Epilepsy, Pain Management, Anti-Psychotics,Anti-Depressants and Other Markets Independently Analyzedwith Annual Sales Figures in US$ Million for Years 2004through 2009 (includes corresponding Graph/Chart) III-66
Table 56: German 15-Year Perspective for CNS Therapeutics byProduct Group - Percentage Breakdown of Dollar Sales forAnti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, PainManagement, Anti-Psychotics, Anti-Depressants and OtherMarkets for 2004, 2012 & 2018 (includes correspondingGraph/Chart) III-67
3c. ITALY III-68A.Market Analysis III-68Current & Future Analysis III-68Market Snapshots III-68Strategic Corporate Development III-68B.Market Analytics III-69Table 57: Italian Recent Past, Current & Future Analysis forCNS Therapeutics by Product Group - Anti-Alzheimer's,Anti-Parkinson's, Anti-Epilepsy, Pain Management,Anti-Psychotics, Anti-Depressants and Other MarketsIndependently Analyzed with Annual Sales Figures in US$Million for Years 2010 through 2018 (includes correspondingGraph/Chart) III-69
Table 58: Italian Historic Review for CNS Therapeutics byProduct Group - Anti-Alzheimer's, Anti-Parkinson's,Anti-Epilepsy, Pain Management, Anti-Psychotics,Anti-Depressants and Other Markets Independently Analyzedwith Annual Sales Figures in US$ Million for Years 2004through 2009 (includes corresponding Graph/Chart) III-70
Table 59: Italian 15-Year Perspective for CNS Therapeuticsby Product Group - Percentage Breakdown of Dollar Sales forAnti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, PainManagement, Anti-Psychotics, Anti-Depressants and OtherMarkets for 2004, 2012 & 2018 (includes correspondingGraph/Chart) III-71
3d. THE UNITED KINGDOM III-72A.Market Analysis III-72Current & Future Analysis III-72NICE Recommendations on CNS Therapeutics III-72Product Launches III-72Strategic Corporate Developments III-75Key Players III-76B.Market Analytics III-80Table 60: UK Recent Past, Current & Future Analysis for CNSTherapeutics by Product Group - Anti-Alzheimer's,Anti-Parkinson's, Anti-Epilepsy, Pain Management,Anti-Psychotics, Anti-Depressants and Other MarketsIndependently Analyzed with Annual Sales Figures in US$Million for Years 2010 through 2018 (includes correspondingGraph/Chart) III-80
Table 61: UK Historic Review for CNS Therapeutics by ProductGroup - Anti-Alzheimer's, Anti-Parkinson's, Anti-E
To order this report:Therapy Industry: Global CNS Therapeutics Industry
__________________________Contact Clare: [email protected] US:(339) 368 6001 Intl:+1 339 368 6001
SOURCE Reportlinker
